Heron Therapeutics, INC /DE/ Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on August 6, 2026.
NASDAQ
Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 31, 2026.
NASDAQ
William P Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 30, 2026.
NASDAQ
Ira Duarte, EVP, Chief Financial Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 30, 2026.
NASDAQ
Craig A Collard, Chief Executive Officer and a Director of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 30, 2026.
NASDAQ
Craig A Collard, Chief Executive Officer and a Director of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.
NASDAQ
William P Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.
NASDAQ
Ira Duarte, EVP, Chief Financial Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.
NASDAQ
Heron Therapeutics EVP, Chief Financial Officer Ira Duarte acquired 12,500 shares of common stock through restricted stock units.
NASDAQ
Heron Therapeutics EVP, Chief Development Officer William P. Forbes acquired 12,500 shares of common stock through the vesting of restricted stock units.
NASDAQ
Heron Therapeutics Chief Operating Officer Mark Hensley acquired 125,000 restricted stock units on May 6, 2026.
NASDAQ
Heron Therapeutics Chief Operating Officer Mark Hensley reported a transaction involving 11,770 shares of common stock.
NASDAQ
Heron Therapeutics EVP, Chief Development Officer William P. Forbes acquired company stock through the vesting of restricted stock units.
NASDAQ
Heron Therapeutics EVP and CFO, Ira Duarte, acquired shares through restricted stock units and an employee stock purchase plan.
NASDAQ
Heron Therapeutics, Inc. executive Craig Collard reported transactions involving common stock and restricted stock units.
NASDAQ
William P. Forbes, EVP, Chief Development Officer at Heron Therapeutics, Inc., acquired 3,874 shares of common stock on April 19, 2026.
NASDAQ
Heron Therapeutics, Inc. reports a transaction involving Chief Executive Officer Craig A. Collard, who acquired 13,797 shares of common stock.
NASDAQ
Heron Therapeutics EVP, CFO Ira Duarte acquired 3,874 shares of common stock through the vesting of restricted stock units.
NASDAQ
Heron Therapeutics Chief Executive Officer, Craig A. Collard, acquired 62,500 shares of common stock.
NASDAQ
Heron Therapeutics CEO Craig Collard was granted over 1.6 million restricted and performance stock units, vesting quarterly starting in 2026.
NASDAQ
Heron Therapeutics Director Christian Waage was granted 53,960 restricted stock units, vesting in full on January 30, 2027.
NASDAQ
Heron Therapeutics Director Michael Kaseta was granted 53,960 restricted stock units, vesting in full on January 30, 2027.
NASDAQ
Heron Therapeutics' EVP and CFO, Ira Duarte, received significant equity grants comprising Restricted Stock Units and Performance Stock Units, vesting over four years.
NASDAQ
Heron Therapeutics Director Craig A. Johnson was granted 53,960 restricted stock units, vesting in full on January 30, 2027.
NASDAQ
Heron Therapeutics Director Thomas Cusack was granted 53,960 restricted stock units, vesting in full on January 30, 2027.
NASDAQ
Heron Therapeutics' EVP, Chief Development Officer William P. Forbes, received grants of 188,315 Restricted Stock Units and 188,314 Performance Stock Units, vesting over four years.
NASDAQ
Heron Therapeutics Director Sharmila Dissanaike was granted 53,960 restricted stock units, vesting fully on January 30, 2027.
NASDAQ
Heron Therapeutics' Chief Operating Officer, Mark Earl Hensley, was granted 188,315 Restricted Stock Units and 188,314 Performance Stock Units.
NASDAQ
Heron Therapeutics director Adam Morgan received a grant of 53,960 restricted stock units, aligning his interests with shareholders.
NASDAQ
Heron Therapeutics' EVP and CFO, Ira Duarte, converted 11,695 restricted stock units into common stock on January 31, 2026.